abstract |
The present invention provides a prophylactic or therapeutic agent for benign prostatic hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS), comprising a quinazoline derivative as an active ingredient. Further, the present invention provides a composition comprising a quinazoline derivative for use in the treatment or prevention of BPH and LUTS, and a method for preventing or treating BPH and LUTS, including administering an agent or a composition comprising a quinazoline derivative to a mammal including a human. The BPH prophylactic or therapeutic agent or composition ofthe present invention has excellent PDE5 inhibitory effects, exhibits low inhibitory activity on PDE6 and PDE11 at a dose exhibiting PDE5 inhibitory activity, thus providing less side effects, has a moderate blood half-life as compared to other PDE5 inhibitors and therefore can exert sufficient medicinal efficacy even with single administration/day without risk of drug accumulation,thus providing increased drug compliance and excellent metabolic stability. |